# Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma

> **NCT02546544** · PHASE2 · COMPLETED · sponsor: **University of Oxford** · enrollment: 16 (actual)

## Conditions studied

- Relapsed Ewing Sarcoma
- Refractory Ewing Sarcoma

## Interventions

- **DRUG:** Linsitinib

## Key facts

- **NCT ID:** NCT02546544
- **Lead sponsor:** University of Oxford
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2016-07-15
- **Final completion:** 2016-07-15
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2019-06-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02546544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02546544, "Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02546544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*